Y7G Stock Overview
A clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BioAge Labs, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.60 |
| 52 Week High | US$24.10 |
| 52 Week Low | US$16.95 |
| Beta | 0 |
| 11 Month Change | 22.38% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 22.38% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| Y7G | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.4% | -4.1% | -1.0% |
| 1Y | n/a | -11.4% | 16.1% |
Return vs Industry: Insufficient data to determine how Y7G performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how Y7G performed against the German Market.
Price Volatility
| Y7G volatility | |
|---|---|
| Y7G Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.7% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: Y7G's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine Y7G's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 59 | Kristen Fortney | bioagelabs.com |
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults.
BioAge Labs, Inc. Fundamentals Summary
| Y7G fundamental statistics | |
|---|---|
| Market cap | €777.16m |
| Earnings (TTM) | -€57.15m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-13.6x
P/E RatioIs Y7G overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| Y7G income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$62.16m |
| Earnings | -US$62.16m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.74 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 7.8% |
How did Y7G perform over the long term?
See historical performance and comparison